Brody agreed. "Because indolent lymphomas are generally considered incurable, the development of novel and, ideally, safer therapies is urgently needed by our patients," he said.
"Additional trials studying bendamustine for other types of lymphoma and in combination with newer targeted therapies are under way," he added. "Taken together, the recent advances in lymphoma therapy are extremely encouraging for our patients and for progress in oncology overall."
Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.
Find out more about non-Hodgkin lymphomas at the Leukemia & Lymphoma Society.
Copyright © 2012 HealthDay. All rights reserved.